Switch theme
Sign up to access all valuation multiples
Hugel Inc is a biopharmaceutical company. It is in the business of manufacturing of biopharmaceuticals. The company's primary products are Botulinum toxin, Hyaluronic acid filler, and Cosmetics. It develops and promotes its products under the brand name of Wellage. The firm has manufacturing facilities in Shinbuk and Geodu.
2001
n/a
LTM Revenue $269M
LTM EBITDA $134M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hugel has a last 12-month revenue of $269M and a last 12-month EBITDA of $134M.
In the most recent fiscal year, Hugel achieved revenue of $254M and an EBITDA of $124M.
Hugel expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hugel valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $218M | $254M | XXX | XXX | XXX |
| Gross Profit | $149M | $168M | XXX | XXX | XXX |
| Gross Margin | 68% | 66% | XXX | XXX | XXX |
| EBITDA | $102M | $124M | XXX | XXX | XXX |
| EBITDA Margin | 47% | 49% | XXX | XXX | XXX |
| Net Profit | $39.1M | $63.4M | XXX | XXX | XXX |
| Net Margin | 18% | 25% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hugel's stock price is KRW 346500 (or $236).
Hugel has current market cap of KRW 3.73T (or $2.5B), and EV of KRW 3.34T (or $2.3B).
See Hugel trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.5B | XXX | XXX | XXX | XXX | $8.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hugel has market cap of $2.5B and EV of $2.3B.
Hugel's trades at 8.5x LTM EV/Revenue multiple, and 17.0x LTM EBITDA.
Analysts estimate Hugel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hugel and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 9.0x | XXX | XXX | XXX |
| EV/EBITDA | 18.4x | XXX | XXX | XXX |
| P/E | 27.5x | XXX | XXX | XXX |
| P/E/Growth | 1.0x | XXX | XXX | XXX |
| EV/FCF | 28.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHugel's NTM/LTM revenue growth is 21%
Hugel's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Hugel's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hugel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hugel and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 49% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 70% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 32% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hugel acquired XXX companies to date.
Last acquisition by Hugel was XXXXXXXX, XXXXX XXXXX XXXXXX . Hugel acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hugel founded? | Hugel was founded in 2001. |
| Where is Hugel headquartered? | Hugel is headquartered in South Korea. |
| Is Hugel publicy listed? | Yes, Hugel is a public company listed on KRX. |
| What is the stock symbol of Hugel? | Hugel trades under 145020 ticker. |
| When did Hugel go public? | Hugel went public in 2015. |
| Who are competitors of Hugel? | Similar companies to Hugel include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hugel? | Hugel's current market cap is $2.5B |
| What is the current revenue of Hugel? | Hugel's last 12-month revenue is $269M. |
| What is the current EBITDA of Hugel? | Hugel's last 12-month EBITDA is $134M. |
| What is the current EV/Revenue multiple of Hugel? | Current revenue multiple of Hugel is 8.5x. |
| What is the current EV/EBITDA multiple of Hugel? | Current EBITDA multiple of Hugel is 17.0x. |
| What is the current revenue growth of Hugel? | Hugel revenue growth between 2023 and 2024 was 17%. |
| Is Hugel profitable? | Yes, Hugel is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
